We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
30 Jan 2023 - 02 Feb 2023

Tau Radiotracer Aids Alzheimer's Disease Diagnosis

By MedImaging International staff writers
Posted on 11 Jun 2020
Print article
A novel diagnostic radiotracer can help estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adults being evaluated for Alzheimer’s disease (AD).

Developed by Avid Radiopharmaceuticals (Philadelphia, PA, USA), a wholly owned subsidiary of Eli Lilly (Indianapolis, IN, USA), Tauvid (flortaucipir 18F) radiotracer is a small-molecule selective positron emission tomography (PET) imaging agent that binds to aggregated tau protein, which in the brains of patients with AD, combine to form NFTs, one of the two components required for the neuropathological diagnosis of AD. The safety and effectiveness of the tau tracer were demonstrated in two clinical studies.

The first study included 156 terminally ill patients who agreed to undergo Tauvid PET imaging and to donate their brains after death; 64 died within nine months of brain scanning. Five evaluators' readings were then compared to post mortem readings from independent pathologists, who were blinded to the PET scan results. The results showed that the five evaluator’s readings had a high probability of correctly evaluating patients with tau pathology and had an average-to-high probability of correctly evaluating patients without tau pathology.

The second study included the same patients with terminal illness that participated in the first study, but with an additional 18 patients with terminal illness and 159 patients with cognitive impairment who were being evaluated for AD. In this second study, reader agreement was 0.87 across all 241 patients. In a separate subgroup analysis that included the 82 terminally ill patients who were diagnosed after death and the 159 patients with cognitive impairment, reader agreement was 0.90 for the AD patients and 0.82 in the terminally ill patients.

“The fight against Alzheimer’s disease requires precise and reliable assessments of the two key pathologies of the disease, because clinical assessments alone are limited in their ability to accurately diagnose patients,” said Mark Mintun, MD, vice president of Lilly's pain and neurodegeneration research and development. “Lilly and Avid Radiopharmaceuticals are committed to bringing innovative AD diagnostics to the patients who need them most.”

“Diagnostic imaging can help patients and their families plan for the future and make informed choices about their health and well-being, in addition to facilitating appropriate patient management for physicians,” said professor of neurology Reisa Sperling, MD, of Harvard Medical School (Boston, MA, USA). “Determining the anatomic distribution and density of tau NFTs in the brain was previously possible only at autopsy. Now we have a way to obtain this important information in patients.”

18F is a fluorine radioisotope that decays by positron emission 97% of the time, and electron capture 3% of the time; both modes of decay yield stable oxygen-18 (18O). 18F is an important radioisotope as a result of both its short half-life and the emission of positrons when decaying. It is primarily synthesized into fluorodeoxyglucose (FDG) for use in PET scans.

Related Links:
Avid Radiopharmaceuticals
Eli Lilly



Print article
Radcal
CIRS -  MIRION

Channels

MRI

view channel
Image: Hyperpolarized MRI technology reveals changes in heart muscle’s sugar metabolism after heart attack (Photo courtesy of ETH Zurich)

MRI Technology to Visualize Metabolic Processes in Real Time Could Improve Heart Disease Diagnosis

Magnetic resonance imaging (MRI) has become an indispensable part of medicine. It allows unique insights into the body and diagnosis of various diseases. However, current MRI technology has its limitations:... Read more

Ultrasound

view channel
Image: A combination of ultrasound and nanobubbles allows cancerous tumors to be destroyed without surgery (Photo courtesy of Tel Aviv University)

Ultrasound Combined With Nanobubbles Enables Removal of Tumors Without Surgery

The prevalent method of cancer treatment is surgical removal of the tumor, in combination with complementary treatments such as chemotherapy and immunotherapy. Therapeutic ultrasound to destroy the cancerous... Read more

General/Advanced Imaging

view channel
Image: AI tool predicts reduced blood flow to the heart (Photo courtesy of Pexels)

AI Tool Uses CT Scans to Identify Patients at Risk of Reduced Blood Flow to the Heart

Blockages of the coronary arteries typically occur due to the buildup of fatty plaques. This may restrict blood flow to the heart, causing chest pain, heart attacks, or even death. Identifying which arteries... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.